RESUMEN
The incidences of total fracture, major fracture, and hip fractures in primary care in Southern Brazil were 22.3, 15.0, and 3.3 per 1000 person/year. The FRAX algorithm showed an adequate discriminatory capacity for the identification of these fractures. OBEJECTIVE: Few studies are evaluating the incidence of fractures in Latin America and Brazil. This study aimed to estimate the incidence of bone fractures in postmenopausal women seen in primary care and evaluate the FRAX algorithm's performance in these women. METHODS: A cohort study was carried out in the municipality of Santa Maria, Southern Brazil. Postmenopausal women aged 55 years and over who attended primary health care were included. The recruitment period was from March 1 to August 31, 2013, and the participants were followed for 5 years. The fracture risk was calculated using the FRAX algorithm. The reported incident fractures were confirmed by imaging studies or surgical reports. RESULTS: Of the 1057 women recruited for the study, 854 were followed. They contributed to 2732 person/year. The mean follow-up time was 3.2 years (SD 1.05). The incidences of total fractures, major fractures, and hip fractures were 22.3, 15.0, and 3.3 per 1000 person/year. The most frequent fracture sites were the wrist, shoulder, and ribs. The fracture predictors were rheumatoid arthritis, previous fracture, and the use of glucocorticoids. The discriminatory capacity of incident fractures calculated by FRAX without the inclusion of BMD was AUC 0.730 (95% CI 0.570, 0.890) for hip fracture and AUC 0.691 (95% CI 0.598, 0.784) for major fractures. CONCLUSION: The FRAX algorithm showed an adequate discriminatory capacity to identify incident fractures in primary care in our study. The incidence of fractures found in our study appears to be lower than that reported in North America and Europe.
Asunto(s)
Fracturas de Cadera , Fracturas Osteoporóticas , Densidad Ósea , Brasil/epidemiología , Estudios de Cohortes , Femenino , Fracturas de Cadera/epidemiología , Humanos , Incidencia , Fracturas Osteoporóticas/epidemiología , Posmenopausia , Atención Primaria de Salud , Medición de Riesgo , Factores de RiesgoRESUMEN
Objective: To evaluate the link between calcium supplementa- tion and cardiovascular disease in postmenopausal women (aged 55 years or older). Methods: A standardized questionnaire was employed to collect data about calcium supplements, eart di- sease, and demographic of women attended at Primary Care in the South Region of Brazil. Generalized linear regression models were performed to evaluate the association and adjust for poten- tial confounders. Results: Overall, 1,057 women completed the questionnaire. Information about calcium supplementation was present in 1,035 questionnaires. The mean ± standard deviation of the age of participants was 67.2±7.6 years. The frequency of calcium supplementation was 18.6%. There was no association between heart failure, stroke, and ischemic heart disease and cal- cium supplementation (prevalence ratio; 95% confidence interval of 0.3; -0.9-0.4, -0.2; -0.8-0.4 and -0.5; -1.0-0.02, respectively. Con- clusions: Our study did not find an association of higher risk of cardiovascular disease in women using calcium supplementation at Primary Care in South Brazil.
Objetivo: Avaliar a ligação entre a suplementação de cálcio e doença cardiovascular em mulheres na pós-menopausa (com 55 anos ou mais). Métodos: Um questionário padronizado foi em- pregado para coletar dados sobre suplementos de cálcio, doenças cardíacas e demográficos de mulheres que frequentavam a Aten- ção Primária na Região Sul do Brasil. Modelos de regressão linear generalizada foram realizados para avaliar a associação e ajustar os potenciais fatores de confusão. Resultados: No total, 1.057 mulheres responderam ao questionário. As informações sobre su- plementação de cálcio estavam presentes em 1.035 questionários. A média ± desvio-padrão da idade dos participantes foi de 67,2 ± 7,6 anos. A frequência de suplementação de cálcio foi de 18,6%. Não houve associação entre insuficiência cardíaca, acidente vas- cular cerebral e doença cardíaca isquêmica e suplementação de cálcio (razão de prevalência; intervalo de confiança de 95% de -0,3; -0,9-0,4, -0,2; -0,8-0,4 e -0,5; -1,0-0,02, respectivamente). Con- clusão: Nosso estudo não encontrou associação de maior risco de doença cardiovascular em mulheres em uso de suplementação de cálcio na Atenção Primária no Sul do Brasil.
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Anciano , Atención Primaria de Salud , Enfermedades Cardiovasculares/inducido químicamente , Posmenopausia , Compuestos de Calcio/administración & dosificación , Suplementos Dietéticos/efectos adversos , Vitamina D/administración & dosificación , Brasil , Estudios Transversales , Encuestas y Cuestionarios , Accidente Cerebrovascular/inducido químicamente , Conservadores de la Densidad Ósea/administración & dosificación , Factores de Riesgo de Enfermedad CardiacaRESUMEN
BACKGROUND: The Indian Takayasu Clinical Activity Score (ITAS2010) was developed in 2010 as an assessment tool for disease activity in patients with Takayasu arteritis (TA). It has since been widely used in different studies and in clinical practice for the management of patients with TA. The present study aims to translate the ITAS2010 into Brazilian Portuguese language and to validate it for use in clinical practice in Brazil. METHODS: For this cross-sectional study, the ITAS2010 was translated in accordance with the guidelines described by Beaton et al. and then applied with 27 patients with TA on three assessments by two rheumatologists working independently. To measure interrater agreement, the assessments were performed on the same day within approximately 1 hour. One of the rheumatologists performed a second evaluation of patients with TA within 7 to 14 days to measure intrarater agreement. RESULTS: The correlation coefficient for the ITAS2010 score between the two raters was high (r = 0.916; p < 0.0001), as well as the intraclass correlation coefficient (ICC) [0.918 with a 95% confidence interval (95CI): 0.828-0.962]. The correlation coefficient and the ICC for intrarater agreement were moderate for ITAS2010 (r = 0.633; p < 0.0001 and ICC = 0.594; 95CI: 0.292-0.790). The ITAS2010 at baseline was compared with the physician's global assessment (PGA) and with Kerr's criteria for detecting disease activity in TA. Higher ITAS2010 scores were observed in patients with active and grumbling/persistent disease than in those presenting inactive disease according to the PGA [1.5 (0.0-3.0) vs. 0.0 (0.0-0.0); p = 0.0025]. Patients with active disease according to the Kerr's criteria had also higher ITAS2010 scores than those considered in remission [3.0 (3.0-7.0) vs. 0.0 (0.0-0.0); p = 0.0068]. CONCLUSIONS: The Brazilian Portuguese version of the ITAS2010 is a valid and reproducible tool for the assessment of disease activity in TA and it is an additional tool for the routine evaluation of Brazilian patients with TA.
Asunto(s)
Lenguaje , Arteritis de Takayasu/diagnóstico , Traducciones , Adulto , Sedimentación Sanguínea , Intervalos de Confianza , Estudios Transversales , Femenino , Humanos , Masculino , Registros Médicos , Variaciones Dependientes del Observador , Examen Físico/métodos , Examen Físico/normas , Estudios Prospectivos , Reproducibilidad de los Resultados , Evaluación de Síntomas/métodos , Arteritis de Takayasu/diagnóstico por imagen , Arteritis de Takayasu/terapiaRESUMEN
Abstract Background: The Indian Takayasu Clinical Activity Score (ITAS2010) was developed in 2010 as an assessment tool for disease activity in patients with Takayasu arteritis (TA). It has since been widely used in different studies and in clinical practice for the management of patients with TA. The present study aims to translate the ITAS2010 into Brazilian Portuguese language and to validate it for use in clinical practice in Brazil. Methods: For this cross-sectional study, the ITAS2010 was translated in accordance with the guidelines described by Beaton et al. and then applied with 27 patients with TA on three assessments by two rheumatologists working independently. To measure interrater agreement, the assessments were performed on the same day within approximately 1 hour. One of the rheumatologists performed a second evaluation of patients with TA within 7 to 14 days to measure intrarater agreement. Results: The correlation coefficient for the ITAS2010 score between the two raters was high (r =0.916; p < 0.0001), as well as the intraclass correlation coefficient (ICC) [0.918 with a 95% confidence interval (95CI): 0.828-0.962]. The correlation coefficient and the ICC for intrarater agreement were moderate for ITAS2010 (r =0.633; p < 0.0001 and ICC = 0.594; 95CI: 0.292-0.790). The ITAS2010 at baseline was compared with the physician's global assessment (PGA) and with Kerr's criteria for detecting disease activity in TA. Higher ITAS2010 scores were observed in patients with active and grumbling/persistent disease than in those presenting inactive disease according to the PGA [1.5 (0.0-3.0) vs. 0.0 (0.0-0.0); p = 0.0025]. Patients with active disease according to the Kerr's criteria had also higher ITAS2010 scores than those considered in remission [3.0 (3.0-7.0) vs. 0.0 (0.0-0.0); p = 0.0068]. Conclusions: The Brazilian Portuguese version of the ITAS2010 is a valid and reproducible tool for the assessment of disease activity in TA and it is an additional tool for the routine evaluation of Brazilian patients with TA.
Asunto(s)
Humanos , Vasculitis , Arteritis de Takayasu , Estudios Transversales/instrumentación , Evaluación de Resultado en la Atención de SaludRESUMEN
Although fractures had high mortality and morbidity, many studies proved that fracture risk might be decreased by pharmacological therapy, although a low treatment adherence rate is observed. The aim of this study was to identify factors associated with osteoporosis treatment in postmenopausal women.A cross-sectional study was carried out from March to August 2013 at the primary care setting. Postmenopausal women were recruited. A standardized questionnaire was applied. Women who were using at least one of the following drugs at the moment of the survey were considered as current treatment: bisphosphonates, raloxifene, estrogen, calcitonin, teriparatide, or strontium ranelate. Women who had used any of the mentioned medications before the study were considered as past treatment.Of the 1025 women included in the study, 8% were on current treatment, 5.7% had past treatment, and 86.3% had not received treatment. Treated women (either current or past) had a higher rate of osteoarthritis, had more falls, had higher education level, presented a higher rate of private health insurance, and received more information about osteoporosis. They also had more dual-energy x-ray absorptiometry (DXA) scans and were more frequently diagnosed with osteoporosis by these DXA scans. The factors independently associated with treatment in the regression analysis were the DXA scan itself, the diagnosis of osteoporosis by DXA, and information about osteoporosis.Current and past treatments of osteoporosis were associated with DXA and information. These results suggest that some measures to inform women about osteoporosis and or even the popularization of DXA scans could improve the treatment.
Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Osteoporosis Posmenopáusica/tratamiento farmacológico , Absorciometría de Fotón/estadística & datos numéricos , Anciano , Estudios Transversales , Femenino , Humanos , Osteoporosis Posmenopáusica/complicaciones , Educación del Paciente como Asunto/estadística & datos numéricos , Posmenopausia , Encuestas y CuestionariosRESUMEN
Although health-related quality of life is well studied in subjects with obesity or fractures, there are few studies approaching both diseases together. The aim of this study was to evaluate the health-related quality of life (HRQL) in obese postmenopausal women with fractures. A cross-sectional study was carried out at Santa Maria, Brazil. Postmenopausal women aged 55 years or older were recruited from March 1st to August 31st, 2013. Women with cognitive impairment were excluded. The Short-Form Health Survey (SF-36) were applied (QM0 16,471). Height and weight were measured according to the World Health Organization protocol. Bone fractures (excluding hand, feet, and head) that occur after age 45 years were considered as the outcome. Of the 1057 women allocated to study, 975 had their weight and height measured. Obese women with fractures had significantly lower SF-36 physical component scores when compared with non-obese subjects with fracture, obese subjects without fractures, and non-obese non-fracture subjects. Both obesity and fractures were independently associated with a lower SF-36 physical component score in the regression model. In conclusion, fractures appear to have an adverse effect on quality of life which is more pronounced in obese postmenopausal women.
RESUMEN
Obesity and osteoporosis are chronic disorders with increasing prevalence worldwide. The aim of this study was to investigate the association between obesity and fracture in postmenopausal women from Santa Maria, Brazil. A cross-sectional study was carried out at Santa Maria (parallel 29° south), Brazil. Postmenopausal women aged ≥55 yr who had at least 1 appointment at the primary care in the 2 years before the study were recruited from March 1, 2013 to August 31, 2013. The Global Longitudinal Study of Osteoporosis in Women study questionnaire was applied with permission of The Center for Outcomes Research, University of Massachusetts Medical School. Height and weight were measured according to the World Health Organization protocol. Bone fractures (excluding hand, feet, and head) that occurred after the age of 45 yr were considered as the outcome. Overall, 1057 women completed the study, of whom 984 had body mass index measured. The mean (standard deviation) age and body mass index of the women included in the study were 67.1 (7.6) yr and 29.2 (5.5) kg/m(2), respectively. The prevalence of fractures in obese and nonobese women was similar (17.3% vs 16.0%); 41.4% of all fractures occurred in obese women. Obese postmenopausal women make a substantial contribution to the overall burden of prevalent fractures in this population. Our results provide further evidence in support of the concept that obesity is not protective against fracture.
Asunto(s)
Accidentes por Caídas/estadística & datos numéricos , Fracturas Óseas/epidemiología , Obesidad/epidemiología , Posmenopausia , Atención Primaria de Salud , Delgadez/epidemiología , Anciano , Índice de Masa Corporal , Densidad Ósea , Brasil/epidemiología , Estudios Transversales , Femenino , Humanos , Persona de Mediana Edad , Sobrepeso/epidemiología , Factores de RiesgoRESUMEN
A hipercalcemia é um problema clínico relativamente comum na prática clínica; todavia, o seu diagnóstico e manejo são pouco discutidos em nível ambulatorial. Esta revisão visa discutir o diagnóstico de hipercalcemia, suas manifestações clínicas, principais causas e princípios de tratamento em nível de atenção primária em saúde. Considera-se hipercalcemia quando o cálcio total ou ionizado encontra-se no limite superior da normalidade, com níveis superiores a 10,5 mg/dl para o cálcio total. Em indivíduos em que não haja alteração do pH e das proteínas, a aferição do cálcio total é extremamente confiável e não existe motivo para a solicitação de cálcio ionizado. A principal causa de hipercalcemia em pacientes ambulatoriais é o hiperparatireoidismo primário; entretanto, valores de cálcio total superiores a 13 mg/dl não são usuais nestes pacientes, e a presença de neoplasia deve ser investigada. O tratamento da hipercalcemia objetiva reduzir os níveis séricos de cálcio e, se possível, tratar a doença de base. A terapia inicial da hipercalcemia inclui simultaneamente a hidratação com solução salina e o uso de calcitonina e bisfosfonatos. Indivíduos com níveis séricos superiores a 13,5 mg/dl devem ser encaminhados a um serviço de emergência (AU)
Hypercalcemia is a relatively common clinical problem in clinical practice; however, its diagnosis and management are hardly discussed at an outpatient level. This review discusses the diagnosis of hypercalcemia, its clinical manifestations, main causes and principles of treatment at the level of primary health care. A diagnosis of hypercalcemia is made when the total or ionized calcium is in the upper limit of normality, with total calcium levels above 10.5 mg/dL. In subjects where there is no change in pH and proteins, measurement of total calcium is extremely reliable and there is no reason for requesting ionized calcium. The main cause of hypercalcemia in outpatients is primary hyperparathyroidism; however, total calcium values greater than 13 mg/dl are unusual in these patients and the presence of neoplasm should be investigated. Treatment aims to reduce serum calcium levels and if possible treat the underlying disease. Initial therapy of hypercalcemia includes simultaneous hydration with saline and the use of calcitonin and bisphosphonates. Individuals with serum levels higher than 13.5 mg/dL should be referred to an emergency department (AU)